Cargando…

MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation

The absorption of L-thyroxine (L-T4) is influenced by several factors, such as patient’s age, drugs interference, absorption kinetics, dietary habits, adherence to therapy. Issues in the L-T4 absorption could be encountered by patients affected by celiac disease, because of drug malabsorption. We en...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrari, Silvia Martina, Fallahi, Poupak, Elia, Giusy, Ragusa, Francesca, Paparo, Sabrina Rosaria, Caruso, Claudia, Ruffilli, Ilaria, Antonelli, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551142/
http://dx.doi.org/10.1210/js.2019-MON-625
_version_ 1783424344507023360
author Ferrari, Silvia Martina
Fallahi, Poupak
Elia, Giusy
Ragusa, Francesca
Paparo, Sabrina Rosaria
Caruso, Claudia
Ruffilli, Ilaria
Antonelli, Alessandro
author_facet Ferrari, Silvia Martina
Fallahi, Poupak
Elia, Giusy
Ragusa, Francesca
Paparo, Sabrina Rosaria
Caruso, Claudia
Ruffilli, Ilaria
Antonelli, Alessandro
author_sort Ferrari, Silvia Martina
collection PubMed
description The absorption of L-thyroxine (L-T4) is influenced by several factors, such as patient’s age, drugs interference, absorption kinetics, dietary habits, adherence to therapy. Issues in the L-T4 absorption could be encountered by patients affected by celiac disease, because of drug malabsorption. We enrolled 22 patients with celiac disease and high serum thyrotropin (TSH) levels in treatment with L-T4 in tablet formulation. All subjects switched to a L-T4 liquid formulation, with no change in the dosage. A circulating TSH levels normalisation/reduction has been obtained in all the patients after the switch from L-T4 in tablet formulation to an oral liquid one with the same L-T4 dosage. Nine subjects switched back again to receive L-T4 in tablets (at the same dosage) reporting a worsening of TSH levels, and TSH values fell into the hypothyroid range. In conclusion, malabsorption issues could be overcome through oral L-T4 liquid formulation administration, in this way leading to ameliorate the management of patients affected by celiac disease.
format Online
Article
Text
id pubmed-6551142
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65511422019-06-13 MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation Ferrari, Silvia Martina Fallahi, Poupak Elia, Giusy Ragusa, Francesca Paparo, Sabrina Rosaria Caruso, Claudia Ruffilli, Ilaria Antonelli, Alessandro J Endocr Soc Thyroid The absorption of L-thyroxine (L-T4) is influenced by several factors, such as patient’s age, drugs interference, absorption kinetics, dietary habits, adherence to therapy. Issues in the L-T4 absorption could be encountered by patients affected by celiac disease, because of drug malabsorption. We enrolled 22 patients with celiac disease and high serum thyrotropin (TSH) levels in treatment with L-T4 in tablet formulation. All subjects switched to a L-T4 liquid formulation, with no change in the dosage. A circulating TSH levels normalisation/reduction has been obtained in all the patients after the switch from L-T4 in tablet formulation to an oral liquid one with the same L-T4 dosage. Nine subjects switched back again to receive L-T4 in tablets (at the same dosage) reporting a worsening of TSH levels, and TSH values fell into the hypothyroid range. In conclusion, malabsorption issues could be overcome through oral L-T4 liquid formulation administration, in this way leading to ameliorate the management of patients affected by celiac disease. Endocrine Society 2019-04-30 /pmc/articles/PMC6551142/ http://dx.doi.org/10.1210/js.2019-MON-625 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Thyroid
Ferrari, Silvia Martina
Fallahi, Poupak
Elia, Giusy
Ragusa, Francesca
Paparo, Sabrina Rosaria
Caruso, Claudia
Ruffilli, Ilaria
Antonelli, Alessandro
MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation
title MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation
title_full MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation
title_fullStr MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation
title_full_unstemmed MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation
title_short MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation
title_sort mon-625 serum tsh levels normalisation in patients with celiac disease after the switch from oral l-t4 in tablet form to l-t4 in liquid formulation
topic Thyroid
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551142/
http://dx.doi.org/10.1210/js.2019-MON-625
work_keys_str_mv AT ferrarisilviamartina mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation
AT fallahipoupak mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation
AT eliagiusy mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation
AT ragusafrancesca mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation
AT paparosabrinarosaria mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation
AT carusoclaudia mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation
AT ruffilliilaria mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation
AT antonellialessandro mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation